March 2024
1. LI CMF, MacDougall K, Fraser JA
   Teaching NeuroImage: Transcalvarial Lymphoma: A Rare Cause of Secondary Intracranial Hypertension.
   Neurology. 2024;102:e209227.
   

   >> Share

   
   August 2023
2. GRIFFIN KJ, Toledano M, Flanagan EP, Mustafa R, et al
   "Trident Sign" in Primary CNS B-Cell Spinal Cord Lymphoma.
   Neurology. 2023 Aug 30:10.1212/WNL.0000000000207671.
   

   >> Share

   
   
3. RATTANAWONG W, Tekarjnavanit A, Marukatat C, Hemachudha P, et al
   Teaching NeuroImage: Branching Dura Mater in Primary Central Nervous System, ALK-Positive, Anaplastic Large Cell Lymphoma.
   Neurology. 2023 Aug 3:10.1212/WNL.0000000000207752.
   

   >> Share

   
   
4. KARSCHNIA P, Kurz SC, Brastianos PK, Winter SF, et al
   Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Primary CNS Lymphoma Patients Treated With Methotrexate-Based Regimens.
   Neurology. 2023 Aug 1:10.1212/WNL.0000000000207670.
   

   >> Share

   
   June 2023
5. THERKELSEN KE, Schaff LR, Nandakumar S, Omuro AMP, et al
   Long-term Outcomes in Primary CNS Lymphoma Following R-MVP and High Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.
   Neurology. 2023 Jun 21:10.1212/WNL.0000000000207490.
   

   >> Share

   
   May 2023
6. 
   Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
   Neurology. 2023 May 3:10.1212/WNL.0000000000207470.
   

   >> Share

   
   April 2023
7. KARSCHNIA P, Rejeski K, Subklewe M, von Baumgarten L, et al
   Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
   Neurology. 2023;100:687-688.
   

   >> Share

   
   
8. LEWIS A, Galetta S
   Editors' Note: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
   Neurology. 2023;100:687.
   

   >> Share

   
   
9. TAN BJ, Chan LL, Tan EK
   Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
   Neurology. 2023;100:688.
   

   >> Share

   
   March 2023
10. LU L, Zhu A, Itoh CY, Coburn RP, et al
    CNS T-Cell Lymphoma Many Years After Hemophagocytic Lymphohistiocytosis.
    Neurology. 2023 Mar 28:10.1212/WNL.0000000000207244.
    

    >> Share

    
    July 2022
11. URSU R, Maillet D, Belin C, Moroni C, et al
    Long-Term Neurological Safety in B-Cell Lymphoma Patients Treated With Anti-CD19 CAR T-Cell Therapy.
    Neurology. 2022 Jul 18. pii: WNL.0000000000201083.
    

    >> Share

    
    March 2022
12. KARSCHNIA P, Rejeski K, Winkelmann M, Schoberl F, et al
    Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
    Neurology. 2022 Mar 29. pii: WNL.0000000000200608.
    

    >> Share

    
    September 2021
13. HOUILLIER C, Chabrot CM, Moles-Moreau MP, Willems L, et al
    Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.
    Neurology. 2021;97:628-631.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share